长春高新：子公司GenSci141软膏境内生产药品注册临床试验申请获批

Core Viewpoint - Changchun High-tech Industry (Group) Co., Ltd. announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial application of GenSci141 ointment, a drug aimed at treating conditions related to androgen deficiency in children [2]. Group 1 - The GenSci141 ointment is a dihydrotestosterone ointment classified as a chemical drug of categories 2.2 and 2.4 [2]. - The indications for GenSci141 include treatment for conditions such as hypergonadotropic hypogonadism, 5α-reductase type 2 deficiency, congenital adrenal hyperplasia due to reduced androgen synthesis, and idiopathic causes leading to micropenis in children [2]. - Currently, there are no approved drugs for the treatment of micropenis in children, highlighting a significant market opportunity for GenSci141 [2]. Group 2 - The company stated it will actively promote the research and development of the project and will comply with relevant regulations to disclose subsequent progress in a timely manner [2].